Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity
Authors:
Open Access
- 15 March 2023
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 30 (1) , 2189118
Abstract
Doxorubicin (DOX), a commonly used anti-cancer drug, is limited by its cardiotoxicity and multidrug resistance (MDR) of tumor cells. Epigallocatechin gallate (EGCG), a natural antioxidant component, can effectively reduce the cardiotoxicity of DOX. Meanwhile, EGCG can inhibit the expression of P-glycoprotein (P-gp) and reverse the MDR of tumor cells. In this study, DOX is connected with low molecular weight polyethyleneimine (PEI) via hydrazone bond to get the pH-sensitive PEI-DOX, which is then combined with EGCG to prevent the cardiotoxicity of DOX and reverse the MDR of cancer cells. In addition, folic acid (FA) modified polyethylene glycol (PEG) (PEG-FA) is added to get the targeted system PEI-DOX/EGCG/FA. The MDR reversal and targeting ability of PEI-DOX/EGCG/FA is performed by cytotoxicity and in vivo anti-tumor activity on multidrug resistant MCF-7 cells (MCF-7/ADR). Additionally, we investigate the anti-drug resistant mechanism by Western Blot. The ability of EGCG to reduce DOX cardiotoxicity is confirmed by cardiotoxicity assay. In conclusion, PEI-DOX/EGCG/FA can inhibit the expression of P-gp and reverse the MDR in tumor cells. It also shows the ability of remove oxygen free radicals effectively to prevent the cardiotoxicity of DOX.Keywords
This publication has 38 references indexed in Scilit:
- ROS-responsive capsules engineered from green tea polyphenol–metal networks for anticancer drug deliveryJournal of Materials Chemistry B, 2018
- Molecular mechanism of doxorubicin-induced cardiomyopathy – An updateEuropean Journal of Pharmacology, 2018
- Synthesis and evaluation of 68Ga‐HBED‐CC‐EDBE‐folate for positron‐emission tomography imaging of overexpressed folate receptors on CT26 tumor cellsJournal of Labelled Compounds and Radiopharmaceuticals, 2017
- (–)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Τhrough the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling PathwaysAnticancer Research, 2017
- Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated reviewCritical Reviews in Food Science and Nutrition, 2017
- Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug ResistanceTheranostics, 2016
- Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal CancersBiological and Pharmaceutical Bulletin, 2015
- A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapyActa Biomaterialia, 2014
- Three Decades of P-gp Inhibitors: Skimming Through Several Generations and ScaffoldsCurrent Medicinal Chemistry, 2012
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007